MX2022000782A - Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt). - Google Patents
Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt).Info
- Publication number
- MX2022000782A MX2022000782A MX2022000782A MX2022000782A MX2022000782A MX 2022000782 A MX2022000782 A MX 2022000782A MX 2022000782 A MX2022000782 A MX 2022000782A MX 2022000782 A MX2022000782 A MX 2022000782A MX 2022000782 A MX2022000782 A MX 2022000782A
- Authority
- MX
- Mexico
- Prior art keywords
- thalassemia
- transfusion
- ferroportin
- tdt
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere al uso de compuestos inhibidores de la ferroportina de la fórmula general (I) para tratar la ß-talasemia dependiente de transfusiones. (ver Fórmula).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19187248 | 2019-07-19 | ||
EP20174230 | 2020-05-12 | ||
PCT/EP2020/070391 WO2021013771A1 (en) | 2019-07-19 | 2020-07-17 | Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt) |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022000782A true MX2022000782A (es) | 2022-04-18 |
Family
ID=71661870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022000782A MX2022000782A (es) | 2019-07-19 | 2020-07-17 | Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt). |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220273634A1 (es) |
EP (1) | EP3999059A1 (es) |
JP (1) | JP2022541782A (es) |
KR (1) | KR20220042149A (es) |
CN (1) | CN114302882A (es) |
AU (1) | AU2020316632A1 (es) |
BR (1) | BR112022001062A2 (es) |
CA (1) | CA3147696A1 (es) |
IL (1) | IL289756A (es) |
MX (1) | MX2022000782A (es) |
WO (1) | WO2021013771A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117999262A (zh) | 2021-09-21 | 2024-05-07 | 威佛(国际)股份公司 | N-取代的膜铁转运蛋白抑制剂 |
WO2024083980A1 (en) | 2022-10-21 | 2024-04-25 | Vifor (International) Ag | Bicyclic ferroportin inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008241483B2 (en) * | 2007-04-18 | 2011-03-24 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
BRPI1014635A8 (pt) * | 2009-06-04 | 2016-10-11 | Nissan Chemical Ind Ltd | compostos heterocíclicos e agentes de expansão para células-tronco hematopoiéticas |
WO2013086312A1 (en) | 2011-12-09 | 2013-06-13 | Ferrokin Biosciences, Inc. | Oral formulations for treating metal overload |
CN107847562A (zh) | 2015-05-13 | 2018-03-27 | 细胞基因公司 | 使用 ACTRII 配体陷阱治疗 β‑地中海贫血 |
EP3365339A1 (en) * | 2015-10-23 | 2018-08-29 | Vifor (International) AG | Novel ferroportin inhibitors |
JOP20180036A1 (ar) * | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
EP3894416B1 (en) | 2018-12-13 | 2022-11-09 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
-
2020
- 2020-07-17 CA CA3147696A patent/CA3147696A1/en active Pending
- 2020-07-17 US US17/627,907 patent/US20220273634A1/en active Pending
- 2020-07-17 JP JP2022502906A patent/JP2022541782A/ja active Pending
- 2020-07-17 KR KR1020227005131A patent/KR20220042149A/ko unknown
- 2020-07-17 CN CN202080052426.5A patent/CN114302882A/zh active Pending
- 2020-07-17 AU AU2020316632A patent/AU2020316632A1/en active Pending
- 2020-07-17 EP EP20742255.1A patent/EP3999059A1/en active Pending
- 2020-07-17 WO PCT/EP2020/070391 patent/WO2021013771A1/en active Application Filing
- 2020-07-17 MX MX2022000782A patent/MX2022000782A/es unknown
- 2020-07-17 BR BR112022001062A patent/BR112022001062A2/pt unknown
-
2022
- 2022-01-11 IL IL289756A patent/IL289756A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL289756A (en) | 2022-03-01 |
CN114302882A (zh) | 2022-04-08 |
JP2022541782A (ja) | 2022-09-27 |
US20220273634A1 (en) | 2022-09-01 |
WO2021013771A1 (en) | 2021-01-28 |
KR20220042149A (ko) | 2022-04-04 |
EP3999059A1 (en) | 2022-05-25 |
CA3147696A1 (en) | 2021-01-28 |
AU2020316632A1 (en) | 2022-02-24 |
BR112022001062A2 (pt) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
EA202190630A1 (ru) | Способы комбинированной терапии | |
MD20160118A2 (ro) | Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1 | |
MX2017012729A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer. | |
MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
MX2022001019A (es) | Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38). | |
EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
EA202193015A1 (ru) | Ингибиторы cdk | |
PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
MX2020007974A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
MX2022001690A (es) | Compuestos deuterados para usarse en el tratamiento del cancer. | |
EA202090900A1 (ru) | Ингибиторы иммунопротеасом | |
MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
MX2022000782A (es) | Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt). | |
EA202192575A1 (ru) | Соединения dbait в сочетании с ингибиторами киназ для лечения рака | |
MX2016016507A (es) | Composiciones y metodos para tratar canceres. |